Eversept Partners Increases Stake in Vera Therapeutics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy VERA?
Source: NASDAQ.COM
- Share Acquisition: Eversept Partners added 264,468 shares of Vera Therapeutics in Q4 2026, with an estimated transaction value of $9.39 million, indicating strong confidence in the company's growth potential.
- Position Value Increase: By quarter-end, Eversept's holdings in Vera appreciated by $73.99 million, reflecting both new purchases and stock price increases, thereby reinforcing its investment portfolio in the biopharmaceutical sector.
- Clinical Advancements: Vera's lead drug candidate, atacicept, is under development for treating immunoglobulin A nephropathy and has shown positive Phase 3 results, with an FDA priority review decision expected in July 2026, potentially leading to a swift market launch.
- Financial Readiness: Ending 2025 with approximately $714 million in cash and marketable securities, Vera's management believes this capital is sufficient to fund operations through potential drug approval and launch, demonstrating a solid strategy for future growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VERA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VERA
Wall Street analysts forecast VERA stock price to rise
12 Analyst Rating
11 Buy
1 Hold
0 Sell
Strong Buy
Current: 40.050
Low
33.00
Averages
74.08
High
100.00
Current: 40.050
Low
33.00
Averages
74.08
High
100.00
About VERA
Vera Therapeutics, Inc. is a late-stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, it is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. It is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. It retains all global developmental and commercial rights to atacicept and MAU868.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eversept Partners Increases Stake in Vera Therapeutics
- Share Acquisition: Eversept Partners disclosed an increase in its stake in Vera Therapeutics by 264,468 shares in Q4 2026, with an estimated transaction value of approximately $9.39 million, indicating strong confidence in the company's prospects.
- Holding Value Surge: By quarter-end, the total value of Eversept's holdings in Vera reached $73.99 million, reflecting both new purchases and stock price appreciation, which underscores market recognition of Vera's future potential.
- FDA Review Progress: Vera's lead drug candidate, atacicept, is under priority review by the FDA, with a decision expected in July 2026; if approved, it could rapidly enter the U.S. market, potentially leading to significant revenue growth.
- Strong Financial Position: Vera ended 2025 with approximately $714 million in cash and marketable securities, sufficient to fund operations through a potential drug launch, demonstrating the company's financial preparedness and strategic planning at a critical juncture.
See More
Eversept Partners Increases Stake in Vera Therapeutics
- Share Acquisition: Eversept Partners added 264,468 shares of Vera Therapeutics in Q4 2026, with an estimated transaction value of $9.39 million, indicating strong confidence in the company's growth potential.
- Position Value Increase: By quarter-end, Eversept's holdings in Vera appreciated by $73.99 million, reflecting both new purchases and stock price increases, thereby reinforcing its investment portfolio in the biopharmaceutical sector.
- Clinical Advancements: Vera's lead drug candidate, atacicept, is under development for treating immunoglobulin A nephropathy and has shown positive Phase 3 results, with an FDA priority review decision expected in July 2026, potentially leading to a swift market launch.
- Financial Readiness: Ending 2025 with approximately $714 million in cash and marketable securities, Vera's management believes this capital is sufficient to fund operations through potential drug approval and launch, demonstrating a solid strategy for future growth.
See More
Deerfield Increases Stake in Vera Therapeutics
- Share Acquisition: Deerfield Management Company increased its stake in Vera Therapeutics (VERA) by 418,538 shares during Q4 2025, with an estimated transaction value of approximately $14.87 million, indicating strong confidence in the company's prospects.
- Increased Ownership: Following this acquisition, Deerfield's ownership in Vera Therapeutics rose to about 2.6%, highlighting its significance in the investment portfolio and reinforcing long-term investment beliefs in the company.
- Stock Performance: As of February 17, 2026, Vera's shares were priced at $42.85, reflecting a 50% increase over the past year, significantly outperforming the S&P 500's 19% gain, showcasing market optimism regarding its future developments.
- Clinical Progress: Vera's lead drug candidate, atacicept, is in Phase IIb clinical trials, and the FDA has granted priority review, with a decision expected on July 7, 2026; if approved, this could transition the company from a clinical-stage biotech to a commercial player in immunology.
See More
Vertex's Experimental Drug Trial Success Boosts Shares by 9%
- Successful Drug Trial: Vertex Pharmaceuticals' experimental drug povetacicept succeeded in a Phase 3 trial for a rare kidney condition, reducing levels of a disease marker by 52%, surpassing analyst expectations and indicating significant potential for expansion into kidney diseases.
- Positive Stock Reaction: Following the trial results, Vertex's shares rose over 9% on Tuesday, reflecting market optimism regarding the prospects of its new drug development, which could provide a new revenue stream for the company.
- Future Revenue Expectations: Analyst Carter Gould from Cantor Fitzgerald predicts that the two drugs Vertex is developing alongside povetacicept could generate over $10 billion in annual revenue, potentially rivaling the company's cystic fibrosis franchise that generated over $11 billion in sales last year.
- FDA Application Plans: Vertex plans to submit its application for povetacicept for IgAN to the U.S. FDA by the end of this month, with approval possible later this year through a priority review voucher, further solidifying the company's strategy in the kidney disease market.
See More
Vertex's Drug Success in Phase 3 Trial Paves Way for Kidney Disease Expansion
- Successful Drug Trial: Vertex Pharmaceuticals' drug povetacicept succeeded in a Phase 3 trial for a rare kidney condition, achieving a 52% reduction in a marker of the autoimmune disease, surpassing analyst expectations and indicating significant market potential.
- Positive Market Reaction: Following the trial results, Vertex's shares rose over 9% on Tuesday, reflecting investor confidence in the company's expansion into kidney disease, which could lay the groundwork for future revenue growth.
- Significant Revenue Potential: Analyst Carter Gould estimates that povetacicept and its follow-up drugs could generate over $10 billion annually for Vertex, a figure that approaches the $11 billion in sales from its cystic fibrosis drugs last year, highlighting the strategic importance of this new market.
- FDA Application Imminent: Vertex plans to submit its application for povetacicept to the U.S. FDA by the end of this month, with potential approval later this year, which would accelerate its positioning in the kidney disease treatment landscape and enhance the company's competitive edge.
See More
Analysis of VERA Options Trading and Risks
- Options Selling Risks: Selling puts on VERA does not provide the same upside potential as owning shares, as the seller only acquires shares if the contract is exercised, indicating higher risk.
- Yield Analysis: Unless VERA's stock price falls by 22.5% and the contract is exercised, the only upside for the seller comes from collecting a 12.5% annualized return on the option premium, highlighting limited potential gains.
- Volatility Indicator: VERA's trailing twelve-month volatility is calculated at 85%, which, when combined with fundamental analysis, can assist investors in assessing whether the $30 strike put option is worth the risk.
- Market Trading Dynamics: In mid-afternoon trading on Monday, the put volume among S&P 500 components reached 1.08 million contracts, equal to call volume, indicating a higher demand for puts than the long-term median level.
See More
Eversept Partners Increases Stake in Vera Therapeutics
- Share Acquisition: Eversept Partners disclosed an increase in its stake in Vera Therapeutics by 264,468 shares in Q4 2026, with an estimated transaction value of approximately $9.39 million, indicating strong confidence in the company's prospects.
- Holding Value Surge: By quarter-end, the total value of Eversept's holdings in Vera reached $73.99 million, reflecting both new purchases and stock price appreciation, which underscores market recognition of Vera's future potential.
- FDA Review Progress: Vera's lead drug candidate, atacicept, is under priority review by the FDA, with a decision expected in July 2026; if approved, it could rapidly enter the U.S. market, potentially leading to significant revenue growth.
- Strong Financial Position: Vera ended 2025 with approximately $714 million in cash and marketable securities, sufficient to fund operations through a potential drug launch, demonstrating the company's financial preparedness and strategic planning at a critical juncture.
See More
Eversept Partners Increases Stake in Vera Therapeutics
- Share Acquisition: Eversept Partners added 264,468 shares of Vera Therapeutics in Q4 2026, with an estimated transaction value of $9.39 million, indicating strong confidence in the company's growth potential.
- Position Value Increase: By quarter-end, Eversept's holdings in Vera appreciated by $73.99 million, reflecting both new purchases and stock price increases, thereby reinforcing its investment portfolio in the biopharmaceutical sector.
- Clinical Advancements: Vera's lead drug candidate, atacicept, is under development for treating immunoglobulin A nephropathy and has shown positive Phase 3 results, with an FDA priority review decision expected in July 2026, potentially leading to a swift market launch.
- Financial Readiness: Ending 2025 with approximately $714 million in cash and marketable securities, Vera's management believes this capital is sufficient to fund operations through potential drug approval and launch, demonstrating a solid strategy for future growth.
See More
Deerfield Increases Stake in Vera Therapeutics
- Share Acquisition: Deerfield Management Company increased its stake in Vera Therapeutics (VERA) by 418,538 shares during Q4 2025, with an estimated transaction value of approximately $14.87 million, indicating strong confidence in the company's prospects.
- Increased Ownership: Following this acquisition, Deerfield's ownership in Vera Therapeutics rose to about 2.6%, highlighting its significance in the investment portfolio and reinforcing long-term investment beliefs in the company.
- Stock Performance: As of February 17, 2026, Vera's shares were priced at $42.85, reflecting a 50% increase over the past year, significantly outperforming the S&P 500's 19% gain, showcasing market optimism regarding its future developments.
- Clinical Progress: Vera's lead drug candidate, atacicept, is in Phase IIb clinical trials, and the FDA has granted priority review, with a decision expected on July 7, 2026; if approved, this could transition the company from a clinical-stage biotech to a commercial player in immunology.
See More
Vertex's Experimental Drug Trial Success Boosts Shares by 9%
- Successful Drug Trial: Vertex Pharmaceuticals' experimental drug povetacicept succeeded in a Phase 3 trial for a rare kidney condition, reducing levels of a disease marker by 52%, surpassing analyst expectations and indicating significant potential for expansion into kidney diseases.
- Positive Stock Reaction: Following the trial results, Vertex's shares rose over 9% on Tuesday, reflecting market optimism regarding the prospects of its new drug development, which could provide a new revenue stream for the company.
- Future Revenue Expectations: Analyst Carter Gould from Cantor Fitzgerald predicts that the two drugs Vertex is developing alongside povetacicept could generate over $10 billion in annual revenue, potentially rivaling the company's cystic fibrosis franchise that generated over $11 billion in sales last year.
- FDA Application Plans: Vertex plans to submit its application for povetacicept for IgAN to the U.S. FDA by the end of this month, with approval possible later this year through a priority review voucher, further solidifying the company's strategy in the kidney disease market.
See More
Vertex's Drug Success in Phase 3 Trial Paves Way for Kidney Disease Expansion
- Successful Drug Trial: Vertex Pharmaceuticals' drug povetacicept succeeded in a Phase 3 trial for a rare kidney condition, achieving a 52% reduction in a marker of the autoimmune disease, surpassing analyst expectations and indicating significant market potential.
- Positive Market Reaction: Following the trial results, Vertex's shares rose over 9% on Tuesday, reflecting investor confidence in the company's expansion into kidney disease, which could lay the groundwork for future revenue growth.
- Significant Revenue Potential: Analyst Carter Gould estimates that povetacicept and its follow-up drugs could generate over $10 billion annually for Vertex, a figure that approaches the $11 billion in sales from its cystic fibrosis drugs last year, highlighting the strategic importance of this new market.
- FDA Application Imminent: Vertex plans to submit its application for povetacicept to the U.S. FDA by the end of this month, with potential approval later this year, which would accelerate its positioning in the kidney disease treatment landscape and enhance the company's competitive edge.
See More
Analysis of VERA Options Trading and Risks
- Options Selling Risks: Selling puts on VERA does not provide the same upside potential as owning shares, as the seller only acquires shares if the contract is exercised, indicating higher risk.
- Yield Analysis: Unless VERA's stock price falls by 22.5% and the contract is exercised, the only upside for the seller comes from collecting a 12.5% annualized return on the option premium, highlighting limited potential gains.
- Volatility Indicator: VERA's trailing twelve-month volatility is calculated at 85%, which, when combined with fundamental analysis, can assist investors in assessing whether the $30 strike put option is worth the risk.
- Market Trading Dynamics: In mid-afternoon trading on Monday, the put volume among S&P 500 components reached 1.08 million contracts, equal to call volume, indicating a higher demand for puts than the long-term median level.
See More
